Malignant Melanoma
📧 Sign up to get email alerts when something new happens for Malignant Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-27Clinical Trial Results: A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma [Phase 1, Phase 2]
A multicenter Phase 1/2 study evaluating recombinant vaccinia virus therapy for malignant melanoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2026-06-18Clinical Trial Results: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 [Phase 1]
Phase 1 trial of GD2-SADA:177Lu-DOTA complex for GD2-expressing solid tumors was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors [Phase 2]
Phase 2 trial evaluating rigosertib in combination with pembrolizumab for unresectable or metastatic melanoma that is refractory to PD-1 inh…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies [Phase 1]
Pfizer's Phase 1 trial of PF-08046037 alone or with sasanlimab in advanced cancers has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies [Phase 1]
Phase 1 clinical trial evaluating CTX-8371 in patients with advanced malignancies, including Non-Small Cell Lung Cancer and Triple-Negative …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
A completed Travera Inc trial evaluating TraveraRTGx and a tumor-cell biomarker intended to guide rapid therapy decisions across multiple ca…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) [Phase 2]
This is a Phase 2 clinical study evaluating the combination of Intismeran Autogene (V940) and pembrolizumab (MK-3475) for malignant melanoma…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Reducing Symptom Burden Through Physical Exercise in Melanoma Patients [NA]
A clinical trial is evaluating whether a structured physical exercise program can reduce symptom burden in patients with malignant melanoma.…
-
CLINICAL_TRIALS other · 2026-03-19Clinical Trial Update: Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma [Phase 2]
Phase 2b trial update for RAPA-201 cell therapy in melanoma, with the study currently not yet recruiting.
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma [Phase 3]
Phase 3 trial assessing short immunotherapy after radical surgery in patients with high-risk malignant melanoma; recruitment is ongoing.
-
CLINICAL_TRIALS safety_alert · 2026-03-06Clinical Trial Update: Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma
A completed clinical trial reports retinal changes associated with BRAF/MEK inhibitor therapy in patients with malignant melanoma, highlight…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma [NA]
This entry provides an update on a clinical trial investigating how the gastrointestinal microbiome influences response to immunotherapy in …
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors [NA]
Completed clinical trial update describing retinal structural and functional changes in patients treated with BRAF/MEK inhibitors. The repor…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors [Phase 2]
A Phase 2 study evaluating vobramitamab duocarmazine in metastatic castration-resistant prostate cancer and other solid tumors was terminate…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201) [Phase 1, Phase 2]
A phase 1/2 study evaluating SAR444245 in combination with cemiplimab for advanced skin cancers (malignant melanoma and squamous cell carcin…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update reports a Phase Ib/II study of TCC1727 in combination therapy for advanced solid tumors, including non-small cell…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating JMT108 Injection for unresectable locally advanced or metastatic malignant melanoma is currently recr…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC [Phase 1]
Phase 1 trial evaluating LB-LR1109 alone and in combination with atezolizumab for solid tumors, including non-small cell lung cancer, curren…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis [NA]
Clinical trial update on fecal microbiota transplantation to treat checkpoint inhibitor–induced diarrhea and colitis; currently RECRUITING a…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement [Phase 1]
A first-in-human Phase 1 trial of PF-07284890 in patients with BRAF V600 mutant solid tumors, including those with brain involvement, has be…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
An observational clinical trial from OncoHost Ltd. aims to predict responsiveness to anti-cancer treatments in patients with advanced cancer…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer [Phase 2]
Phase 2 study evaluating the performance of Gallium-68 labeled FAPI PET/CT for cancer imaging, including patients with malignant melanoma st…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Modified Vaccine for High Risk or Low Residual Melanoma Patients [Phase 1, Phase 2]
Clinical trial update describing a phase 1/2 study of a modified vaccine for patients with high-risk or low residual malignant melanoma; rec…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer [Phase 1]
Chiome Bioscience's CBA-1205, an anti-DLK1 monoclonal antibody, is in a Phase I first-in-human trial for advanced solid tumors including hep…